Oryzon Genomics S.a.

Matthew Colin Thor Fyfe

Alberto Ortega Muñoz

Marc Martinell Pedemonte

Julio Cesar Castro-Palomino Laria

Nuria Valls Vidal

Julio Cesar Castro Palomino Laria

Guido Kurz

Maria De Los Àngeles Estiarte Martinez

Iñigo Tirapu Fernandez De La Cuesta

Jonathan Alleman Baker

Maria De Los Ángeles Estiarte-Martinez

Tamara Maes

Maria De Los Ángeles Estiarte Martinez

María De Los Ángeles Estiarte Martínez

Maria De Los Ángeles Estiarte-Martínez

Núrla Valls Vidal

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A&#x2032;) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, &#x2014;CHC(=0)NH, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is &#x2014;NH&#x2014;; (L) is chosen from a single bond, &#x2014;CH&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CHCHCH&#x2014;, and &#x2014;CHCHCHCH&#x2014;; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from &#x2014;NH, &#x2014;NH(C-Calkyl), &#x2014;N(C-Calkyl)(C-Calkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A&#x2032;)X-(A)-(B)&#x2014;(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.

Lysine specific demethylase-1 inhibitors and their use

The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

Lysine demethylase inhibitors for myeloproliferative disorders

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. 

Cyclopropylamine derivatives useful as LSD1 inhibitors

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

[object Object]

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A&#x2032;) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, &#x2014;CHC(&#x2550;0)NH, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is &#x2014;NH&#x2014;; (L) is chosen from a single bond, &#x2014;CH&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CHCHCH&#x2014;, and &#x2014;CHCHCHCH&#x2014;; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from &#x2014;NH, &#x2014;NH(C-Calkyl), &#x2014;N(C-Calkyl)(C-Calkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A&#x2032;)X-(A)-(B)&#x2014;(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. 

Growing community of inventors

Chipping Norton, United Kingdom

Matthew Colin Thor Fyfe